NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #162
PRACTICAL GASTROENTEROLOGY • APRIL 2017 35
Protein Losing Enteropathy: Diagnosis and Management
9. Udink Ten Cate FE, Hannes T, Germund I, et al. Towards a
proposal for a universal diagnostic denition of protein-losing
enteropathy in Fontan patients: a systematic review. Heart
(British Cardiac Society). 2016;102(14):1115-1119.
10. Strygler B, Nicar MJ, Santangelo WC, et al. Alpha 1-antitryp-
sin excretion in stool in normal subjects and in patients with
gastrointestinal disorders. Gastroenterology. 1990;99(5):1380-
1387.
11. Takeda H, Nishise S, Furukawa M, et al. Fecal clear-
ance of alpha1-antitrypsin with lansoprazole can detect pro-
tein-losing gastropathy. Digestive diseases and sciences.
1999;44(11):2313-2318.
12. Chau TN, Mok MY, Chan EY, et al. Evaluation of perfor-
mance of measurement of faecal alpha(1)-antitrypsin clear-
ance and technetium-99m human serum albumin scintigraphy
in protein-losing enteropathy. Digestion. 2011;84(3):199-206.
13. John AS, Johnson JA, Khan M, et al. Clinical outcomes and
improved survival in patients with protein-losing enteropathy
after the Fontan operation. J Am Coll Cardiol. 2014;64(1):54-
62.
14. Takenaka H, Ohmiya N, Hirooka Y, et al. Endoscopic
and imaging ndings in protein-losing enteropathy. J Clin
Gastroenterol. 2012;46(7):575-580.
15. Tift WL, Lloyd JK. Intestinal lymphangiectasia. Long-term
results with MCT diet. Arch Dis Child. 1975;50(4):269-276.
16. Law ST, Ma KM, Li KK. Protein-losing enteropathy associ-
ated with or without systemic autoimmune disease: what are
the differences? Eur J Gastroenterol Hepatol. 2012;24(3):294-
302.
17. Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy
after fontan operation: investigations into possible pathophysi-
ologic mechanisms. Ann Thorac Surg. 2006;82(2):695-700.
18. Patel JK, Loomes KM, Goldberg DJ, et al. Early Impact of
Fontan Operation on Enteric Protein Loss. Ann Thorac Surg.
2016;101(3):1025-1030.
19. Thacker D, Patel A, Dodds K, et al. Use of oral budesonide in
the management of protein-losing enteropathy after the Fontan
operation. Ann Thorac Surg. 2010;89(3):837-842.
20. Jacobs ML, Rychik J, Byrum CJ, et al. Protein-losing enter-
opathy after Fontan operation: resolution after bafe fenestra-
tion. Ann Thorac Surg. 1996;61(1):206-208.
21. Shah ND LB. The Use of Medium-Chain Triglycerides in
Gastrointestinal Disorders. Practical Gastroenterology. 2017.
[In Press]
22. Rychik J, Spray TL. Strategies to treat protein-losing enteropa-
thy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu.
2002;5:3-11.
23. Baert D, Wulfrank D, Burvenich P, et al. Lymph loss in the
bowel and severe nutritional disturbances in Crohn’s disease.
J Clin Gastroenterol. 1999;29(3):277-279.
24. Popovic OS, Brkic S, Bojic P, et al. Sarcoidosis and protein
losing enteropathy. Gastroenterology. 1980;78(1):119-125.
25. Nakaya Y, Hosokawa SK, Kataoka Y, et al. Collagenous
Colitis Associated with Protein-losing Enteropathy. Intern
Med. 2015;54(22):2959-2960.
26. Fushimi T, Takahashi Y, Kashima Y, et al. Severe protein
losing enteropathy with intractable diarrhea due to systemic
AA amyloidosis, successfully treated with corticosteroid and
octreotide. Amyloid. 2005;12(1):48-53.
27. Meuwissen SG, Ridwan BU, Hasper HJ, et al. Hypertrophic
protein-losing gastropathy. A retrospective analysis of 40 cases
in The Netherlands. The Dutch Menetrier Study Group. Scand
J Gastroenterol Suppl. 1992;194:1-7.
28. Yamashita K, Saito M, Itoh M, et al. Juvenile polyposis
complicated with protein losing gastropathy. Intern Med.
2009;48(5):335-338.
29. Siewert E, Lammert F, Koppitz P, et al. Eosinophilic gastro-
enteritis with severe protein-losing enteropathy: successful
treatment with budesonide. Dig Liver Dis. 2006;38(1):55-59.
30. Cohen HA, Shapiro RP, Frydman M, et al. Childhood protein-
losing enteropathy associated with Helicobacter pylori infec-
tion. J Pediatr Gastroenterol Nutr. 1991;13(2):201-203.
31. Freeman HJ. Tropheryma whipplei infection. World J
Gastroenterol. 2009;15(17):2078-2080.
32. Megged O, Schlesinger Y. Cytomegalovirus-associated
protein-losing gastropathy in childhood. Eur J Pediatr.
2008;167(11):1217-1220.
33. Mhanni AA, Kozenko M, Hartley JN, et al. Successful therapy
for protein-losing enteropathy caused by chronic neurono-
pathic Gaucher disease. Mol Genet Metab Rep. 2016;6:13-15.
34. Vignes S, Bellanger J. Primary intestinal lymphangiectasia
(Waldmann’s disease). Orphanet J Rare Dis. 2008;3:5.
35. Tsukamoto A, Nakamura F, Nannya Y, et al. MALT lymphoma
of the small bowel with protein-losing enteropathy. Int J
Hematol. 2014;99(2):198-201.
36. Pratz KW, Dingli D, Smyrk TC, et al. Intestinal lymphangiec-
tasia with protein-losing enteropathy in Waldenstrom macro-
globulinemia. Medicine (Baltimore). 2007;86(4):210-214.
37. Ringel RE, Peddy SB. Effect of high-dose spironolactone
on protein-losing enteropathy in patients with Fontan pal-
liation of complex congenital heart disease. Am J Cardiol.
2003;91(8):1031-1032, A1039.
38. Donnelly JP, Rosenthal A, Castle VP, et al. Reversal of pro-
tein-losing enteropathy with heparin therapy in three patients
with univentricular hearts and Fontan palliation. J Pediatr.
1997;130(3):474-478.
39. Ryerson L, Goldberg C, Rosenthal A, et al. Usefulness of
heparin therapy in protein-losing enteropathy associated with
single ventricle palliation. Am J Cardiol. 2008;101(2):248-
251.
40. Rychik J, Piccoli DA, Barber G. Usefulness of corticosteroid
therapy for protein-losing enteropathy after the Fontan proce-
dure. Am J Cardiol. 1991;68(8):819-821.
41. Turner Z, Lanford L, Webber S. Oral budesonide as a therapy
for protein-losing enteropathy in patients having undergone
Fontan palliation. Congenital heart disease. 2012;7(1):24-30.
42. Gursu HA, Erdogan I, Varan B, et al. Oral budesonide as a
therapy for protein-losing enteropathy in children after the
Fontan operation. J Card Surg. 2014;29(5):712-716.
43. Schumacher KR, Cools M, Goldstein BH, et al. Oral
budesonide treatment for protein-losing enteropathy in Fontan-
palliated patients. Pediatr Cardiol. 2011;32(7):966-971.
44. Filik L, Oguz P, Koksal A, et al. A case with intestinal lym-
phangiectasia successfully treated with slow-release octreo-
tide. Dig Liver Dis. 2004;36(10):687-690.
45. Rothenberg M, Pai R, Stuart K. Successful use of octreotide
to treat Menetrier’s disease: a rare cause of abdominal pain,
weight loss, edema, and hypoalbuminemia. Digestive diseases
and sciences. 2009;54(7):1403-1407.
46. Settle SH, Washington K, Lind C, et al. Chronic treatment
of Menetrier’s disease with Erbitux: clinical efcacy and
insight into pathophysiology. Clin Gastroenterol Hepatol.
2005;3(7):654-659.
47. Ozeki M, Hori T, Kanda K, et al. Everolimus for Primary
Intestinal Lymphangiectasia With Protein-Losing Enteropathy.
Pediatrics. 2016;137(3):e20152562.